Abstract:Tuberculosis (TB), caused by respiratory infection with Mycobacterium tuberculosis , remains a major global health threat. The only licensed TB vaccine, the one-hundred-year-old Bacille Calmette-Guérin has variable efficacy and often provides poor protection against adult pulmonary TB, the transmissible form of the disease. Thus, the lack of an optimal TB vaccine is one of the key barriers to TB control. Recently, the development of highly efficacious COVID-19 vaccines within one year accelerated the vaccine development process in human use, with the notable example of mRNA vaccines and adenovirus-vectored vaccines, and increased the public acceptance of the concept of the controlled human challenge model. In the TB vaccine field, recent progress also facilitated the deployment of an effective TB vaccine. In this review, we provide an update on the current virus-vectored TB vaccine pipeline and summarize the latest findings that might facilitate TB vaccine development. In detail, on the one hand, we provide a systematic literature review of the virus-vectored TB vaccines are in clinical trials, and other promising candidate vaccines at an earlier stage of development are being evaluated in preclinical animal models. These research sharply increase the likelihood of finding a more effective TB vaccine in the near future. On the other hand, we provide an update on the latest tools and concept that facilitating TB vaccine research development. We propose that a pre-requisite for successful development may be a better understanding of both the lung-resident memory T cell-mediated mucosal immunity and the trained immunity of phagocytic cells. Such knowledge could reveal novel targets and result in the innovative vaccine designs that may be needed for a quantum leap forward in vaccine efficacy. We also summarized the research on controlled human infection and ultra-low-dose aerosol infection murine models, which may provide more realistic assessments of vaccine utility at earlier stages. In addition, we believe that the success in the ongoing efforts to identify correlates of protection would be a game-changer for streamlining the triage of multiple next-generation TB vaccine candidates. Thus, with more advanced knowledge of TB vaccine research, we remain hopeful that a more effective TB vaccine will eventually be developed in the near future.

Nanomaterials in Tuberculosis DNA Vaccine Delivery: Historical Perspective and Current Landscape

Nanomaterials in the Prevention, Diagnosis, and Treatment of Mycobacterium Tuberculosis Infections.

New Tuberculosis Vaccine Strategies: Taking Aim at Un-Natural Immunity

Advancements in Nanoparticle-Based Adjuvants for Enhanced Tuberculosis Vaccination: A Review

Induction of an Immune-Protective T-Cell Repertoire with Diverse Genetic Coverage by a Novel Viral-Vectored Tuberculosis Vaccine in Humans

Nanoparticles for DNA Vaccine Delivery

Applications and Perspectives of Nanomaterials in Novel Vaccine Development

Design of nanomaterial based systems for novel vaccine development

Research Advances for Virus-vectored Tuberculosis Vaccines and Latest Findings on Tuberculosis Vaccine Development

Dna Mediated Vaccines Delivery Through Nanoparticles

Current progress of functional nanobiosensors for potential tuberculosis diagnosis: The novel way for TB control?

Nano Vaccines and Nano Materials for Vaccines

An Insight into Advances in Developing Nanotechnology Based Therapeutics, Drug Delivery, Diagnostics and Vaccines: Multidimensional Applications in Tuberculosis Disease Management

Genetic Vaccination Against Tuberculosis

Nanoparticle-Fusion Protein Complexes Protect against Mycobacterium tuberculosis Infection

Biological Nanoparticles in Vaccine Development

Nanomaterial-mediated host directed therapy of tuberculosis by manipulating macrophage autophagy

Carbon nanomaterials: a new way against tuberculosis

DNA and RNA vaccines against tuberculosis: a scoping review of human and animal studies

Systems Approach to Tuberculosis Vaccine Development.

Integration of Novel Materials and Advanced Genomic Technologies into New Vaccine Design